Agios Pharmaceuticals, Inc. to Post Q2 2025 Earnings of ($1.62) Per Share, Zacks Research Forecasts (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Zacks Research boosted their Q2 2025 earnings per share (EPS) estimates for Agios Pharmaceuticals in a report released on Wednesday, May 1st. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn ($1.62) per share for the quarter, up from their previous forecast of ($1.65). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($5.27) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q3 2025 earnings at ($1.56) EPS, Q4 2025 earnings at ($1.65) EPS, FY2025 earnings at ($6.49) EPS, Q1 2026 earnings at ($1.50) EPS and FY2026 earnings at ($5.31) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.64) by $0.19. The business had revenue of $8.19 million during the quarter, compared to analyst estimates of $8.37 million. Agios Pharmaceuticals had a negative return on equity of 39.74% and a negative net margin of 1,199.26%. Agios Pharmaceuticals’s quarterly revenue was up 46.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.47) EPS.

Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. dropped their target price on Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating on the stock in a research report on Friday, February 23rd. Royal Bank of Canada cut their target price on shares of Agios Pharmaceuticals from $43.00 to $42.00 and set an “outperform” rating for the company in a research note on Friday, February 16th. The Goldman Sachs Group raised their price objective on Agios Pharmaceuticals from $29.00 to $33.00 and gave the stock a “neutral” rating in a research note on Friday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, April 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Agios Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $35.00.

Agios Pharmaceuticals Stock Down 0.1 %

Shares of AGIO stock opened at $34.54 on Monday. The firm has a fifty day moving average of $30.61 and a 200-day moving average of $25.68. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -5.47 and a beta of 0.81. Agios Pharmaceuticals has a 12-month low of $19.80 and a 12-month high of $35.50.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in AGIO. China Universal Asset Management Co. Ltd. increased its stake in shares of Agios Pharmaceuticals by 96.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,429 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 700 shares during the period. Quest Partners LLC acquired a new stake in Agios Pharmaceuticals during the 4th quarter worth about $41,000. Headlands Technologies LLC lifted its stake in shares of Agios Pharmaceuticals by 31.3% in the 3rd quarter. Headlands Technologies LLC now owns 9,037 shares of the biopharmaceutical company’s stock valued at $224,000 after purchasing an additional 2,153 shares during the period. NEOS Investment Management LLC bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at about $210,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Agios Pharmaceuticals by 25.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,502 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 2,148 shares in the last quarter.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider James William Burns sold 2,642 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $86,049.94. Following the completion of the transaction, the insider now directly owns 34,518 shares in the company, valued at $1,124,251.26. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Agios Pharmaceuticals news, insider James William Burns sold 2,642 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total transaction of $86,049.94. Following the completion of the transaction, the insider now owns 34,518 shares of the company’s stock, valued at $1,124,251.26. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Brian Goff sold 4,156 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $135,360.92. Following the completion of the sale, the chief executive officer now owns 53,780 shares in the company, valued at $1,751,614.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,035 shares of company stock worth $475,277. Corporate insiders own 4.24% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.